<DOC>
	<DOC>NCT00482391</DOC>
	<brief_summary>The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.</brief_summary>
	<brief_title>Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast Bilateral synchronous breast tumors allowed Any nodal status or tumor size allowed No stage IV disease HER2/neupositive disease 3+ by IHC OR FISHamplified Hormone receptor status not specified PATIENT CHARACTERISTICS: Male or female Menopausal status not specified ECOG performance status 01 Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.1 mg/dL SGOT or SGPT ≤ 2.5 times upper limit of normal (ULN) Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier contraception during and after completion of study therapy LVEF ≥ 50% by MUGA scan No peripheral neuropathy &gt; grade 1 No active second malignancy within the past 5 years except for adequately treated nonmelanoma skin cancer or in situ carcinoma of the cervix No known allergy or hypersensitivity to doxorubicin hydrochloride, cyclophosphamide, paclitaxel, or other drugs formulated in Cremophor EL No psychiatric illness or concurrent medical conditions that would preclude study treatment No other conditions, including any of the following: Unstable angina Congestive heart failure Myocardial infarction within the past 12 months Highrisk uncontrolled arrhythmias (e.g., ventricular tachycardia, highgrade AV block, or supraventricular arrhythmias that are not adequately controlled) No QT prolongation (&gt; 500 ms) No active unresolved infections No sensitivity to E. coli derived proteins PRIOR CONCURRENT THERAPY: Prior hormonal therapy for chemoprevention allowed No prior trastuzumab (Herceptin®) No prior anthracyclines No concurrent hormonal therapy, including hormonal contraception (e.g., birth control pills or ovarian hormonal or replacement therapy) No other concurrent chemotherapy, radiotherapy, immunotherapy, or biotherapy for breast cancer No concurrent drugs that may prolong the QT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>